Trial Site Detail

 

Drug:
GDC-0941 + GDC-0973
Trial:
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions: Solid Tumors
Trial Status:
Completed

 

Sarah Cannon Research Institute

3322 West End Avenue     Suite 900
Nashville , TN 37203
USA

 

Principal Investigator:
Contact:
Activation Status of this Site:
Closed
Notes about this Site:
Sarah Cannon Research Institute Website:
http://www.sarahcannonresearch.com/CustomPage.asp?PageName=Refractory%20Malignancies

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.